Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Camostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 4/20 | 0.72 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.72 |
| ▸ | KLK1 | P06870 | 5/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.63 |
| ▸ | HPN | P05981 | 1/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.63 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
| ▸ | KLK7 | P49862 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL125269 | 0.96 | PRSS1 (0.68) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| SCHEMBL20008640 | 0.96 | PRSS1 (0.68) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL2782237 | 0.95 | PRSS1 (0.67) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL8829828 | 0.94 | PRSS1 (0.66) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL1645380 | 0.93 | PRSS1 (0.64) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL1645520 | 0.92 | PRSS1 (0.63) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL23803656 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL1646099 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL1648303 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2SLC22A2TMPRSS2 | |
| Camostat SCHEMBL2326660 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2SLC22A2TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026089565-A1 | USE OF CATHEPSIN L INHIBITOR IN COMBINATION ADMINISTRATION | 연세대학교 산학협력단 | 2026-04-30 | — | — | WO | claimed |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-04 | — | — | US | claimed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | claimed |
| US-20250152748-A1 | HYDRODYNAMIC GENE DELIVERY | UNIV JOHNS HOPKINS (US) | 2025-05-15 | — | — | US | claimed |
| WO-2025097070-A1 | ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2025097068-A1 | ORAL DOSAGE FORM WITH IONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT AND PERMEATION ENHANCER | ENTREGA INC. (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250127723-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | D&D PHARMATECH INC. (KR) | 2025-04-24 | — | — | US | claimed |
| US-20250099412-A1 | METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-03-27 | — | — | US | claimed |
| WO-2025054715-A1 | COVID-19 TRAP TECHNOLOGY PLATFORM | UNIVERSITY OF MANITOBA (CA) | 2025-03-20 | — | — | WO | claimed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1210063-A4 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE INC (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | claimed |
| US-7045323-B2 | Glutathione reductase for therapy and prophylaxis of aids | ANSOVINI RAFFAELE | 2006-05-16 | — | — | US | claimed |
| WO-2005023835-A2 | MODULATORS OF TRANSMEMBRANE PROTEASE SERINE 6 | IRM LLC (BM) | 2005-03-17 | — | — | WO | claimed |
| US-20050054027-A1 | Modulators of transmembrane protease serine 6 | IRM LLC (BM) | 2005-03-10 | — | — | US | claimed |
| US-20040223958-A1 | Glutathione reductase for therapy and prophylaxis of AIDS | ANSOVINI RAFFAELE (IT) | 2004-11-11 | — | — | US | claimed |
| EP-1210063-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | Lipocine, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| US-6309663-B1 | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents | LIPOCINE INC. | 2001-10-30 | — | — | US | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | F2 1213/4885ADRA1A 3293/4885PRSS1 1209/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | F2 828/4885ADRA1A 2150/4885PRSS1 281/4885 |
| US-20250127723-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LARGE PHYSIOLOGICALLY ACTIVE SUBSTANCE AND EXCIPIENT | CYP7A1, CYP11B1, CYP11B2 | F2 524/4885ADRA1A 408/4885PRSS1 791/4885 |
| US-12458622-B2 | Methods of treatment of coronavirus-induced inflammation conditions | C3AR1, IL5, IL4 | F2 265/4885ADRA1A 2098/4885PRSS1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.